driving innovation to market.
Vol. 1, No. 11 - July, 2013  

UCLA and GSK Reach Agreement on Discovery Fast Track Program
Brendan Rauw
Dear Colleagues,

I am pleased to report we resolved the barriers to faculty participation in the GlaxoSmithKline (GSK) Discovery Fast Track Competition. We encourage faculty who are developing novel drug targets and drug screening assays to consider applying for this program.

When the competition initially launched, we found the terms and conditions to be at odds with UC policies and faculty interests. We took a definitive stand and notified faculty – a position that was supported by many peer institutions.

With the support of the UC Office of the President, we have since resolved the key concerns with GSK. Faculty may submit proposals for developing and conducting screens of GSK’s internal compound collections and thereby advance the development of novel drug targets, pathways and assays. This may lead to further collaborations and/or sponsored research with GSK, thereby helping UCLA move discoveries forward to the clinic for the benefit of patients.

The competition closes on Friday, July 19, 2013. OIP-ISR will work closely with you to determine whether your submission may be appropriate for the program. For more information about the program, and who to contact for assistance, please visit:  http://oip.ucla.edu/gsk-competition.

We look forward to working with you on potential proposal submissions.


Brendan Rauw 
Associate Vice Chancellor and Executive Director of Entrepreneurship

UCLA Licensee, Aragon Pharmaceuticals, Acquired by J&J for up to $1 Billion
Aragon Logo
J&J to receive Aragon’s program for drugs that block androgen, a hormone that can fuel tumors in the prostate.

Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, today announced a definitive agreement with Johnson and Johnson whereby Aragon will be acquired for $650 million in cash up front along with $350 million in contingent development milestone payments that could bring the total transaction value to $1 billion. The acquisition includes Aragon's androgen receptor antagonist program, including its most advanced compound, ARN-509, a second generation androgen receptor signaling inhibitor that is currently being evaluated in a Phase II trial in patients with castration-resistant prostate cancer...

[ Read Full Press Release ]
[ Aragon Pharmaceuticals ]

UCLA Biofuel Startup Raises $1.6 Million in Series "A" Round
Lyxia Logo
Founded by UCLA students, Lyxia to commercialize IP developed at UCLA Micro System Laboratories.

In April 2013, UCLA MAE Ph.D. student Wei Yu raised $1.6M series A venture capital for Lyxia Corporation, a biofuel startup based on research from UCLA MAE Professor Chih-Ming Ho’s Micro System Laboratories. Preceding this, in July 2012, Lyxia Corporation was founded by Wei , and acquired exclusive rights to use new UCLA technology that increases the harvest of microalgae-derived biofuels...

Read Full Article ]
[ Lyxia, Inc. ]

OIP-ISR Hosts SBIR/STTR Training Seminars
SBIR logo
SBIR/STTR grant programs encourage small businesses to collaborate and commercialize new technologies.

UCLA’s OIP-ISR office recently hosted two training sessions on applying for SBIR and STTR grants. The sessions addressed the basics of each funding mechanism and provided tips for drafting successful proposals.

On May 30th, in conjunction with CNSI, OIP-ISR hosted Dr. Marie Talnack, who is an SBIR/STTR consultant and has helped companies apply for grants for over 25 years...

[ Read Full Article | Tips to Consider | SBIR/STTR Links ]

New SBIR/STTR Grants FAQ & Guide Available for UCLA Researchers
SBIR/STTR Guide Logo
RPC and OIP-ISR offer guidance to UCLA employees interested in working with a small company (or startup) to apply for SBIR or STTR funding.

A number of federal agencies, including the Dept. of Health and Human Services, the National Science Foundation, and the Department of Defense, receive congressionally mandated set-aside funding to support R&D activities under the Small Business Innovation (SBIR) and Small Business Technology Transfer (STTR) programs. Among the goals of SBIR/STTR programs is stimulation of technological innovation and private sector commercialization of technology developed through federally-supported R&D...

[ Read SBIR/STTR FAQ and Guide ] pdf

New Technologies Discovered by UCLA Inventors Available for Licensing  
Kinross Bldg.
UCLA technology is commercialized by entrepreneurs and established companies - locally and worldwide.

Prospective Cardiac Motion Self-Gating Technique for Magnetic Resonance Imaging
A novel method for accurate and robust cardiac motion self-gating in magnetic resonance imaging without the need for electrocardiograph gating.

Multi-Apex-Seal Grid for Rotary Engines
A method for designing more efficient rotary engines with increased longevity by reducing leakage and wear at the rotor apex seals.

A microRNA for the Treatment of Pulmonary Hypertension
A specific microRNA that has potential therapeutic utility for treating pulmonary hypertension.

A Novel Device For Quantifying Rotational Stability Of The Knee
A novel device to non-invasively quantify knee stability.

NMR Probe for the Detection of Microstructures
An NMR probe with superior sensitivity for in vivo spectroscopy and detection of ultra small samples.

A Novel Approach for the Treatment of Cushing's Disease
A novel therapeutic strategy for the treatment of Cushing’s disease.



Published by

Research Collaboration, 
and Intellectual Property Commercialization at UCLA. [
subscribe ]


Previous issues of
the UCLA Invents
Newsletter are
available online
First Fridays Logo

Date: July 05, 2013 
Time: 9am-10:30am
Place: Kinross Bldg., Suite 210

Guest Speaker:  Due to the July 4th holiday, no speaker is scheduled for our event this Friday.

Please join us for Coffee, Bagels and Networking at UCLA's Office of Intellectual Property & Industry Sponsored Research (OIP-ISR).

Sign up for our next FirstFridays event!

[ RSVP ]

Patent Image
UCLA patents recently issued by the USPTO:

8,472,685  Apparatus and method for surface capturing and volumetric analysis of multidimensional images | Ai-chi Chien, et al.

8,470,946  Enhanced strength carbon nanotube yarns and sheets using infused and bonded nano-resins | Larry Carlson

8,470,203  Targeting pseudotyped retroviral vectors | Irvin S.Y. Chen, et al.

8,449,875  Fabrication of polyaniline nanofiber dispersions and films | Richard Kaner, et al.

8,460,870  Allosteric control of proteins by manipulating mechanical tension | Giovanni Zocchi, et al.

8,459,295  Localized droplet heating with surface electrodes in microfluidic chips | Chang-Jin Kim, et al.

8,456,629  Apparatus and method for multiple-pulse impulsive stimulated raman spectroscopy | Bahram Jalali, et al.

8,456,074  Flexible nanostructure electronic devices | George Gruner, et al.

8,449,875  Targeting pseudotyped retroviral vectors | Irvin S.Y. Chen, et al.

8,442,353  Incorporation of mathematical constraints in methods for dose reduction and image enhancement in tomography | Jianwei Miao, et al.

8,440,952  Methods for optical amplified imaging using a two-dimensional spectral brush | Bahram Jalali, et al.

8,432,153  Time stretch enhanced recording scope | Bahram Jalali, et al.

8,421,035  High-resolution microscope using optical amplification | Jia-Ming Liu, et al.


 UCLA INVENTS Vol. 1, No. 11

UCLA INVENTS is published by UCLA's Office of Intellectual Property and Industry Sponsored Research (OIP-ISR). UCLA INVENTS highlights entrepreneurial and technology commercialization developments, and opportunities at UCLA.

PLEASE ATTENTION editorial comments, corrections, and topic suggestions to:  
Bob Nidever,   bnidever@research.ucla.edu

  Bob Nidever

  Erin Bowers
  Neil Bajpayee

To subscribe, please visit:   http://oip.ucla.edu/UCLAinvents   

UCLA Office of Intellectual Property and Industry Sponsored Research

11000 Kinross Ave., Suite 200; Los Angeles, CA 90095 | tel. 310-794-0558 |  http://oip.ucla.edu

Copyright 2013 UC Regents

Share this